	US 12,228,567 B2
	Colorimetric sensor kit for screening therapeutic agent for neurodegenerative disease, including amyloid shelled-gold nanoparticle, and method for screening therapeutic agent for neurodegenerative disease
Dae Sung Yoon, Seoul (KR); Dong Tak Lee, Seoul (KR); In Su Kim, Seoul (KR); Gyu Do Lee, Namyangju-si (KR); Hyo Gi Jung, Daegu (KR); and Yong Hwan Kim, Seoul (KR)
Assigned to Korea University Research and Business Foundation, Seoul (KR)
Appl. No. 17/427,413
Filed by Korea University Research and Business Foundation, Seoul (KR)
PCT Filed Nov. 1, 2019, PCT No. PCT/KR2019/014729 § 371(c)(1), (2) Date Jul. 30, 2021, PCT Pub. No. WO2020/166789, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 10-2019-0017328 (KR), filed on Feb. 14, 2019.
Prior Publication US 2022/0099665 A1, Mar. 31, 2022
Int. Cl. G01N 33/543 (2006.01); A61P 25/28 (2006.01); C12Q 1/6816 (2018.01); G01N 33/68 (2006.01); B82Y 15/00 (2011.01); B82Y 30/00 (2011.01)

CPC G01N 33/54346 (2013.01) [A61P 25/28 (2018.01); C12Q 1/6816 (2013.01); G01N 33/6896 (2013.01); B82Y 15/00 (2013.01); B82Y 30/00 (2013.01)]

4 Claims

1. A method for screening a therapeutic agent for a neurodegenerative disease, including:

i) a step of preparing an amyloid shelled-gold nanoparticle wherein an amyloid aggregate is formed as an amyloid protein oligomer as a coating on the surface of a gold nanoparticle;

ii) a step of treating the amyloid shelled-gold nanoparticle with a drug candidate for a therapeutic agent for a neurodegenerative disease;

iii) a step of comparing color change of the amyloid shelled-gold nanoparticle before and after the treatment with the drug candidate; and

iv) a step of screening the drug candidate as a therapeutic agent for a neurodegenerative disease if the amyloid shelled-gold nanoparticle exhibits red color before treating with the drug candidate and its color changes from red to blue when treated with the drug candidate as the amyloid aggregate is degraded.